Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 12/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898107 | 0.91 | ALDH1A1 (0.40) | GRIN2BMEN1LMNAKMT2ABRPF1 | |
| SCHEMBL4591069 | 0.90 | MEN1 (0.38) | GRIN2BMEN1LMNAKMT2AHIF1A | |
| SCHEMBL4591140 | 0.89 | HIF1A (0.37) | GRIN2BMEN1LMNAKMT2AHIF1A | |
| SCHEMBL4900430 | 0.88 | KDM4E (0.41) | MEN1KMT2AHIF1ABRPF1 | |
| SCHEMBL14067465 | 0.88 | HIF1A (0.38) | GRIN2BMEN1KMT2AHIF1ABRPF1 | |
| SCHEMBL4575589 | 0.88 | HRH1 (0.39) | MEN1LMNAKMT2AHIF1ABRPF1 | |
| SCHEMBL5546555 | 0.88 | HDAC3 (0.38) | GRIN2BMEN1KMT2AHIF1AGRIN1 | |
| SCHEMBL4906329 | 0.88 | HIF1A (0.38) | GRIN2BMEN1KMT2AHIF1ABRPF1 | |
| SCHEMBL4576192 | 0.87 | GRIN2B (0.38) | GRIN2BGRIN1 | |
| SCHEMBL4576187 | 0.85 | GRIN2B (0.36) | GRIN2BHIF1AGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | claimed |
| EP-1910363-A2 | HIV INTEGRASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007019098-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | claimed |
| EP-1910363-A2 | HIV INTEGRASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007019098-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | API5, ING2, SAMHD1 | GRIN2B 4068/4885MEN1 4841/4885LMNA 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.